360 related articles for article (PubMed ID: 21334402)
1. Low 25-OH vitamin D serum levels correlate with severe fibrosis in HIV-HCV co-infected patients with chronic hepatitis.
Terrier B; Carrat F; Geri G; Pol S; Piroth L; Halfon P; Poynard T; Souberbielle JC; Cacoub P
J Hepatol; 2011 Oct; 55(4):756-61. PubMed ID: 21334402
[TBL] [Abstract][Full Text] [Related]
2. Low vitamin D levels are associated with impaired virologic response to PEGIFN + RBV therapy in HIV-hepatitis C virus coinfected patients.
Mandorfer M; Reiberger T; Payer BA; Ferlitsch A; Breitenecker F; Aichelburg MC; Obermayer-Pietsch B; Rieger A; Trauner M; Peck-Radosavljevic M;
AIDS; 2013 Jan; 27(2):227-32. PubMed ID: 23238552
[TBL] [Abstract][Full Text] [Related]
3. Vitamin D deficiency is associated with severity of liver disease in HIV/HCV coinfected patients.
Guzmán-Fulgencio M; García-Álvarez M; Berenguer J; Jiménez-Sousa MÁ; Cosín J; Pineda-Tenor D; Carrero A; Aldámiz T; Alvarez E; López JC; Resino S
J Infect; 2014 Feb; 68(2):176-84. PubMed ID: 24184809
[TBL] [Abstract][Full Text] [Related]
4. Changes in liver fibrosis in HIV/HCV-coinfected patients following different outcomes with peginterferon plus ribavirin therapy.
Labarga P; Fernandez-Montero JV; Barreiro P; Pinilla J; Vispo E; de Mendoza C; Plaza Z; Soriano V
J Viral Hepat; 2014 Jul; 21(7):475-9. PubMed ID: 24750394
[TBL] [Abstract][Full Text] [Related]
5. A Lead-In with Silibinin Prior to Triple-Therapy Translates into Favorable Treatment Outcomes in Difficult-To-Treat HIV/Hepatitis C Coinfected Patients.
Braun DL; Rauch A; Aouri M; Durisch N; Eberhard N; Anagnostopoulos A; Ledergerber B; Müllhaupt B; Metzner KJ; Decosterd L; Böni J; Weber R; Fehr J;
PLoS One; 2015; 10(7):e0133028. PubMed ID: 26176696
[TBL] [Abstract][Full Text] [Related]
6. Effect of antiviral treatment on serum markers of liver fibrosis in HIV-hepatitis C virus-coinfected patients: the Fibrovic 2 Study - ANRS HC02.
Halfon P; Carrat F; Bédossa P; Lambert J; Pénaranda G; Perronne C; Pol S; Cacoub P
Antivir Ther; 2009; 14(2):211-9. PubMed ID: 19430096
[TBL] [Abstract][Full Text] [Related]
7. A prospective evaluation of pulmonary, systemic and hepatic haemodynamics in HIV-HCV-coinfected patients before and after antiviral therapy with pegylated interferon and ribavirin.
Reiberger T; Payer BA; Ferlitsch A; Sieghart W; Breitenecker F; Aichelburg MC; Schmied B; Rieger A; Trauner M; Peck-Radosavljevic M;
Antivir Ther; 2012; 17(7):1327-34. PubMed ID: 22948263
[TBL] [Abstract][Full Text] [Related]
8. Liver-related factors associated with low vitamin D levels in HIV and HIV/HCV coinfected patients and comparison to general population.
Milazzo L; Mazzali C; Bestetti G; Longhi E; Foschi A; Viola A; Vago T; Galli M; Parravicini C; Antinori S
Curr HIV Res; 2011 Apr; 9(3):186-93. PubMed ID: 21585333
[TBL] [Abstract][Full Text] [Related]
9. Liver fibrosis progression in HIV-HCV-coinfected patients treated with distinct antiretroviral drugs and impact of pegylated interferon/ribavirin therapy.
Fernández-Montero JV; Barreiro P; Vispo E; Labarga P; Sánchez-Parra C; de Mendoza C; Treviño A; Soriano V
Antivir Ther; 2014; 19(3):287-92. PubMed ID: 24192598
[TBL] [Abstract][Full Text] [Related]
10. Differences in liver fibrosis and response to pegylated interferon plus ribavirin in HIV/HCV-coinfected patients with normal vs elevated liver enzymes.
Maida I; Martin-Carbonero L; Sotgiu G; Vispo E; Barreiro P; Gonzalez-Lahoz J; Soriano V
J Viral Hepat; 2010 Dec; 17(12):866-71. PubMed ID: 20088891
[TBL] [Abstract][Full Text] [Related]
11. Vitamin D status does not predict sustained virologic response or fibrosis stage in chronic hepatitis C genotype 1 infection.
Kitson MT; Dore GJ; George J; Button P; McCaughan GW; Crawford DH; Sievert W; Weltman MD; Cheng WS; Roberts SK
J Hepatol; 2013 Mar; 58(3):467-72. PubMed ID: 23183524
[TBL] [Abstract][Full Text] [Related]
12. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial.
Carrat F; Bani-Sadr F; Pol S; Rosenthal E; Lunel-Fabiani F; Benzekri A; Morand P; Goujard C; Pialoux G; Piroth L; Salmon-Céron D; Degott C; Cacoub P; Perronne C;
JAMA; 2004 Dec; 292(23):2839-48. PubMed ID: 15598915
[TBL] [Abstract][Full Text] [Related]
13. Baseline serum low-density lipoprotein cholesterol levels predict response to hepatitis C virus therapy in HIV/hepatitis C virus coinfected patients.
del Valle J; Mira JA; de los Santos I; López-Cortés LF; Merino D; Rivero A; Girón JA; Ríos-Villegas MJ; González-Serrano M; Collado A; García-García JA; Pineda JA
AIDS; 2008 May; 22(8):923-30. PubMed ID: 18453851
[TBL] [Abstract][Full Text] [Related]
14. Revisiting liver disease progression in HIV/HCV-coinfected patients: the influence of vitamin D, insulin resistance, immune status, IL28B and PNPLA3.
Mandorfer M; Payer BA; Schwabl P; Steiner S; Ferlitsch A; Aichelburg MC; Stättermayer AF; Ferenci P; Obermayer-Pietsch B; Grabmeier-Pfistershammer K; Trauner M; Peck-Radosavljevic M; Reiberger T
Liver Int; 2015 Mar; 35(3):876-85. PubMed ID: 24905495
[TBL] [Abstract][Full Text] [Related]
15. Serum vitamin D₃ does not correlate with liver fibrosis in chronic hepatitis C.
Ren Y; Liu M; Zhao J; Ren F; Chen Y; Li JF; Zhang JY; Qu F; Zhang JL; Duan ZP; Zheng SJ
World J Gastroenterol; 2015 Oct; 21(39):11152-9. PubMed ID: 26494969
[TBL] [Abstract][Full Text] [Related]
16. Effect of Vitamin D Serum Levels and GC Gene Polymorphisms in Liver Fibrosis Due to Chronic Hepatitis C.
Azevedo LA; Matte U; Silveira TR; Bonfanti JW; Bruch JP; Álvares-da-Silva MR
Ann Hepatol; 2017; 16(5):742-748. PubMed ID: 28809744
[TBL] [Abstract][Full Text] [Related]
17. Correlation between vitamin D levels and apoptosis in geriatric patients infected with hepatitis C virus genotype 4.
Gabr SA; Alghadir AH; Allam AA; Ajarem J; Al-Basher G; Abdel-Maksoud MA; Ghfar AA; Aboud A
Clin Interv Aging; 2016; 11():523-33. PubMed ID: 27217734
[TBL] [Abstract][Full Text] [Related]
18. Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C.
Petta S; Cammà C; Scazzone C; Tripodo C; Di Marco V; Bono A; Cabibi D; Licata G; Porcasi R; Marchesini G; Craxí A
Hepatology; 2010 Apr; 51(4):1158-67. PubMed ID: 20162613
[TBL] [Abstract][Full Text] [Related]
19. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons.
Chung RT; Andersen J; Volberding P; Robbins GK; Liu T; Sherman KE; Peters MG; Koziel MJ; Bhan AK; Alston B; Colquhoun D; Nevin T; Harb G; van der Horst C;
N Engl J Med; 2004 Jul; 351(5):451-9. PubMed ID: 15282352
[TBL] [Abstract][Full Text] [Related]
20. Simeprevir (TMC435) with pegylated interferon/ribavirin in patients coinfected with HCV genotype 1 and HIV-1: a phase 3 study.
Dieterich D; Rockstroh JK; Orkin C; Gutiérrez F; Klein MB; Reynes J; Shukla U; Jenkins A; Lenz O; Ouwerkerk-Mahadevan S; Peeters M; De La Rosa G; Tambuyzer L; Jessner W
Clin Infect Dis; 2014 Dec; 59(11):1579-87. PubMed ID: 25192745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
